| Name | Title | Contact Details |
|---|
Capio Partners provides revenue cycle solutions for some of the nation`s leading healthcare providers and hospital systems, converting uncollected receivables into cash. As the healthcare industry moves towards purchasing solutions, Capio Partners offers leadership, knowledge, innovation, and unsurpassed results to help you maximize revenue and minimize risk.
Privis Health is a leading provider of innovative data-driven population health programs and technology rich services that enable healthcare providers to deliver high quality efficient care to their patient population. Our scalable, cloud-based platform empowers healthcare providers to better manage risk, while achieving their operating and performance goals as they transition from fee-for-service to value based reimbursement. In addition, we assist with the design, implementation and expansion of population health programs, while sharing in the accountability for the success of these initiatives. The Privis team has deep experience with a programmatic approach to provide strategies on service models, organizational transformation, quality improvements and learning health system activities. Offerings include care management, care coordination, transitions of care, chronic care management, and complex CCM programs working in tandem with patient engagement and placement services. We provide a tool kit of evidence-based chronic disease and socio-behavioral assessments that drive the creation of a dynamic shared care plan. Our gaps-in-care offering captures important variances in care, such as preventive care, community resources, and guides interventions to assist the patient in achieving better outcomes and appropriate interventions
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Sawtooth Labs is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Tabula Rasa HealthCare family of companies provide new beginnings for our clients, through innovative service models and fresh approaches to healthcare technology. Our leaders understand that to maximize patient experiences and outcomes, they must help providers to balance efficiency and scalability with safety and individualization of care.